Jeffrey H. Samet MD, MA, MPH
Professor, General Internal Medicine
Professor, Community Health Sciences
801 Massachusetts Ave | (617) 414-7444jeff.samet@bmc.org
jsamet@bu.edu
Sections
General Internal Medicine
Centers
Clinical Addiction Research and Education Unit
Evans Center for Interdisciplinary Biomedical Research
Biography
My research has focused on alcohol and drug use, HIV infection and primary medical care with the following specific projects: linkage of alcohol and drug use treatment and primary medical care; addressing alcohol and drug use issues in the primary care setting; the impact of alcohol and drug use in HIV-infected persons; HIV prevention and treatment in Russian substance users; and establishing medical care for HIV-infected persons.
Education
Medicine, MD, Baylor College of Medicine
Epidemiology, MPH, Boston University
Chemistry, MA, Brandeis University
BA, Brandeis University
Publications
Bradley KA, Hyun N, Idu A, Yu O, Bobb JF, Wartko PD, Weinstein Z, Matthews AG, McCormack J, Lee AK, Samet JH. Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial. Addiction. 2026 Mar; 121(3):629-642. PMID: 41287180.
Published on 11/21/2025Rao AV, Ghare SS, Gautam V, Hoffman KL, Petrosino J, So-Armah K, Samet JH, Patts GJ, Cheng DM, Blokhina E, Krupitsky EM, Lioznov D, Zvartau E, McClain CJ, Tindle H, Freiberg MS, Barve SS. Sex differences in beneficial and pathogenic bacteria in People With HIV (PWH) with a history of heavy alcohol drinking. Front Microbiol. 2025; 16:1632949. PMID: 41356481.
Published on 10/15/2025Truong V, Kekibiina A, Muyindike W, Gnatienko N, Tsui JI, Emenyonu NI, Cheng DM, Hahn J, Allison O, Bullard MJ, Lunze K, Samet JH. Gabapentin to achieve HIV viral load suppression in people with risky drinking in Mbarara, Uganda: study protocol for a randomized, double-blinded, placebo-controlled trial (GRAIL). Res Sq. 2025 Oct 15. PMID: 41282191.
Published on 10/11/2025El-Bassel N, Samet JH, Cheng DM, Freisthler B, John Winhusen T, Walsh SL. Response to the Editor: Re: registration and multiple outcome testing in the HEALing Communities Study by Dennis M. Gorman and Ben G. Fitzpatrick. Int J Drug Policy. 2025 Nov; 145:105029. PMID: 41077014.
Published on 9/26/2025Katz R, Fisher T, Singer-Clark T, Soares Iii W, Carpenter J, Schuessler N, Stadler H, Sahovey A, McAlearney AS, Samet JH, Chatterjee A. Creation of a telehealth addiction consultation service at a rural hospital: a case study. Addict Sci Clin Pract. 2025 Sep 26; 20(1):76. PMID: 41013782.
Published on 8/1/2025Tsui JI, Bhatraju EP, Hallgren KA, Rhew IC, Samet JH. High-Dose Buprenorphine Treatment in the Setting of Fentanyl. JAMA Netw Open. 2025 Aug 01; 8(8):e2528119. PMID: 40839262.
Published on 7/29/2025Guyatt P, Babe G, Gayowsky A, Rosic T, Rodrigues M, Bach P, Perez R, de Oliveira C, Samet JH, Kerkerian G, Hann J, Dionne JC, Ahmed A, Kim D, Nolan S, Thabane L, Samaan Z, Dennis BB. Impact of hepatitis C serostatus on health service utilization for opioid-related harms among individuals prescribed opioid agonist therapy: A longitudinal prospective cohort study. Drug Alcohol Depend Rep. 2025 Sep; 16:100368. PMID: 40837618.
Published on 7/9/2025Brown JL, Larochelle MR, Fanucchi LC, Calvert DC, Campbell ANC, Chandler RK, Feaster DJ, Glasgow LM, Gibson EB, Holloway J, Lofwall MR, Mack A, Mack N, Nunes EV, Talbert JC, Tan S, Vandergrift N, Villani J, Asman K, Babakhanlou-Chase H, Bagley SM, Battaglia TA, Blevins D, Bridden C, Cheng DM, Christopher M, Cogan LW, Cunningham CO, Eggleston B, Fareed N, Fernandez S, Freedman DA, Freiermuth CE, Freisthler B, Gilbert L, Hammerslag L, Harris D, Hunt T, Hussain S, Huynh P, Jackson RD, Kauffman EB, Knott C, Knudsen HK, Lefebvre RC, Levin FR, Massatti R, McAlearney AS, Morgan JR, Lopez RM, Lounsbury DW, Newman L, Nickels K, Oga EA, Oller DA, Parran TV, Quinn M, Ramsey KS, Rapkin BD, Salsberry P, Stein M, Taylor JL, Teater J, Walters ST, Zarkin GA, El-Bassel N, Winhusen TJ, Samet JH, Walsh SL. Effects of the Communities That HEAL intervention on initiation, retention, and linkage to medications for opioid use disorder (MOUD): A cluster randomized wait-list controlled trial. Drug Alcohol Depend. 2025 Sep 01; 274:112785. PMID: 40684522.
Published on 7/3/2025Tilhou AS, Assoumou SA, Samet JH. Aligning Efforts to Boost Medications for Opioid Use Disorder and Pre-Exposure Prophylaxis for HIV. J Gen Intern Med. 2026 Jan; 41(2):516-520. PMID: 40610667.
Published on 6/1/2025Magane KM, Dukes KA, Fielman S, Palfai TP, Regan D, Cheng DM, Lee H, Kraemer KL, Bullard MJ, Chen CA, Samet JH. Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2025 Jun 01; 185(6):635-645. PMID: 40257810.
Media Mentions
Published on 6/17/2024
Ambitious federal effort to curb overdoses shows no impact on deaths, initial study finds
Published on 6/17/2024
Community-Based Interventions for Opioid Overdoses Fail to Reduce Deaths in Trial
Published on 9/30/2022
Hospitals have specialists on call for lots of diseases — but not addiction. Why not?
Published on 9/14/2022
Hospitals have many disease specialists, but often not for addiction. Now, that's changing
Published on 8/10/2022
Nicotine Patches, Nasal Sprays May Also Cut Alcohol Consumption: Study
Published on 8/9/2022
Studies conducted with aim to hinder smoking and drinking
Published on 8/8/2022
Published on 6/16/2022
With ‘fentanyl everywhere’ and Black deaths soaring, advocates in Brockton test ways to save lives
Published on 11/18/2021
Drug overdose deaths hit all-time high in the U.S.
Published on 7/7/2021
A Massachusetts Study Aims to Reduce Opioid Overdose Deaths
View full list of 34 media mentions.